Abstract
Objective To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL). Patients and Methods Data were collected from 1450 patients with cHL treated in Israel and Italy from January 1, 1988, through December 31, 2007. Results The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC was 750 cells/mm3, and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more than 750 cells/mm3 was confirmed for the entire cohort, and its clinical significance was particularly evident in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750 cells/mm3 was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm3 or less was 81% (76%-84%; P3 was 78% (70%-85%), and the OS at 10 years for an AMC of 750 cells/mm3 or less was 88% (84%-90%; P=.01). In multivariate analysis, both AMC and LMR maintained prognostic significance for PFS (hazard ratio [HR], 1.54, P=.006, and HR, 1.50, P=.006) after adjusting for the international prognostic score, whereas the impact on OS was confirmed (HR, 1.56; P=.04) only in patients with NS and an AMC of more than 750 cells/mm3. Conclusion This study confirms that AMC has prognostic value in cHL that is particularly significant in patients with NS subtype histology. This finding links the known impact of macrophages and monocytes in Hodgkin lymphoma with routine clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 756-764 |
| Number of pages | 9 |
| Journal | Mayo Clinic Proceedings |
| Volume | 90 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma : Evaluation based on data from 1450 patients. / Tadmor, Tamar; Bari, Alessia; Marcheselli, Luigi; Sacchi, Stefano; Aviv, Ariel; Baldini, Luca; Gobbi, Paolo G.; Pozzi, Samantha; Ferri, Paola; Cox, Maria Christina; Cascavilla, Nicola; Iannitto, Emilio; Federico, Massimo; Polliack, Aaron.
In: Mayo Clinic Proceedings, Vol. 90, No. 6, 01.06.2015, p. 756-764.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma
T2 - Evaluation based on data from 1450 patients
AU - Tadmor, Tamar
AU - Bari, Alessia
AU - Marcheselli, Luigi
AU - Sacchi, Stefano
AU - Aviv, Ariel
AU - Baldini, Luca
AU - Gobbi, Paolo G.
AU - Pozzi, Samantha
AU - Ferri, Paola
AU - Cox, Maria Christina
AU - Cascavilla, Nicola
AU - Iannitto, Emilio
AU - Federico, Massimo
AU - Polliack, Aaron
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Objective To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL). Patients and Methods Data were collected from 1450 patients with cHL treated in Israel and Italy from January 1, 1988, through December 31, 2007. Results The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC was 750 cells/mm3, and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more than 750 cells/mm3 was confirmed for the entire cohort, and its clinical significance was particularly evident in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750 cells/mm3 was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm3 or less was 81% (76%-84%; P3 was 78% (70%-85%), and the OS at 10 years for an AMC of 750 cells/mm3 or less was 88% (84%-90%; P=.01). In multivariate analysis, both AMC and LMR maintained prognostic significance for PFS (hazard ratio [HR], 1.54, P=.006, and HR, 1.50, P=.006) after adjusting for the international prognostic score, whereas the impact on OS was confirmed (HR, 1.56; P=.04) only in patients with NS and an AMC of more than 750 cells/mm3. Conclusion This study confirms that AMC has prognostic value in cHL that is particularly significant in patients with NS subtype histology. This finding links the known impact of macrophages and monocytes in Hodgkin lymphoma with routine clinical practice.
AB - Objective To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL). Patients and Methods Data were collected from 1450 patients with cHL treated in Israel and Italy from January 1, 1988, through December 31, 2007. Results The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC was 750 cells/mm3, and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more than 750 cells/mm3 was confirmed for the entire cohort, and its clinical significance was particularly evident in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750 cells/mm3 was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm3 or less was 81% (76%-84%; P3 was 78% (70%-85%), and the OS at 10 years for an AMC of 750 cells/mm3 or less was 88% (84%-90%; P=.01). In multivariate analysis, both AMC and LMR maintained prognostic significance for PFS (hazard ratio [HR], 1.54, P=.006, and HR, 1.50, P=.006) after adjusting for the international prognostic score, whereas the impact on OS was confirmed (HR, 1.56; P=.04) only in patients with NS and an AMC of more than 750 cells/mm3. Conclusion This study confirms that AMC has prognostic value in cHL that is particularly significant in patients with NS subtype histology. This finding links the known impact of macrophages and monocytes in Hodgkin lymphoma with routine clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84931003455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931003455&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2015.03.025
DO - 10.1016/j.mayocp.2015.03.025
M3 - Article
VL - 90
SP - 756
EP - 764
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 6
ER -